Day: October 26, 2019

UTRECHT, Pays-Bas et BOSTON, 26 oct. 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS) (« Merus », « nous », « notre » ou la « Société »), société spécialisée en immuno-oncologie de stade clinique qui développe Biclonics®, un traitement innovant à base d’anticorps bispécifiques humains pleine longueur, a annoncé aujourd’hui que les données de ses programmes MCLA-128 et MCLA-129 seront présentées lors du Congrès international sur les cibles moléculaires et les thérapeutiques anticancéreuses de l’AACR-NCI-EORTC qui se tiendra du 26 au 30 octobre 2019 à Boston, dans le Massachusetts. Renseignements sur la présentation et l’affiche : MCLA-128Titre de la présentation : Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers (Preuve de concept clinique pour MCLA-128,...

UTRECHT, Niederlande und BOSTON, USA, Oct. 26, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) („Merus‟, „wir‟, „unser‟ oder das „Unternehmen‟), ein Unternehmen für bispezifische Antikörper im klinischen Stadium, das Biclonics®, innovative, vollständige menschliche bispezifische Antikörpertherapeutika entwickelt, gab heute bekannt, dass Daten aus seinen Programmen MCLA-128 und MCLA-129 auf der AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics präsentiert werden, die vom 26. bis 30. Oktober 2019 in Boston, USA, stattfindet. Präsentations- und Posterdetails: MCLA-128PräsentationTitel: Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancersAutoren:  Alison M Schram, Eileen M O’Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan,...

MONCLOVA, Coahuila, Oct. 26, 2019 (GLOBE NEWSWIRE) — Altos Hornos de México, S.A.B. de C.V. and Subsidiaries (“AHMSA” or “the Company”) (BMV: AHMSA) reported financial results for the Third Quarter period ended September 30, 2019 (3Q 2019). Financial and operating figures included in this report are unaudited and are based on AHMSA’s operating figures and financial statements; they are prepared in accordance with International Financial Reporting Standards (IFRS) and are expressed in U.S. dollars (US$) and metric tons (MT), unless otherwise indicated.3Q 2019 HighlightsAdjusted EBITDA was US$ (40.4) million, a 149.6% decline compared to (US$ 81.5 million) in 3Q 2018.  Adjusted EBITDA for the Steel Segment was US$ (31.0) million, a 132.1% decline compared to US$ 96.6 million in 3Q 2018. This result was explained by the following:Steel...

VANCOUVER, British Columbia, Oct. 25, 2019 (GLOBE NEWSWIRE) — Core Gold Inc. (“Core Gold” or the “Company“) (TSX-V: CGLD, OTCQX: CGLDF) is today providing an update regarding the proposed amendments announced by Core Gold on August 21, 2019 to promissory notes issued by Core Gold in the aggregate principal amount of US$1.5 million (the “Promissory Notes“) and (ii) convertible promissory notes issued by Core Gold in the aggregate principal amount of US$1 million (the “Convertible Notes“, and together with the Promissory Notes, the “Core Debt“).As announced by Core Gold on August 21, 2019, Core Gold entered into debt extension and amending agreements (the “Agreements“) with each of Vertex Managed Value Portfolio and Vertex Enhanced Income Fund (collectively, “Vertex“)...